GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • American Society of Hematology  (4)
Material
Publisher
  • American Society of Hematology  (4)
Language
Years
Subjects(RVK)
  • 1
    In: Blood, American Society of Hematology, Vol. 119, No. 3 ( 2012-01-19), p. 884-893
    Abstract: Antiphospholipid Abs (APLAs) are associated with thrombosis and recurrent fetal loss. These Abs are primarily directed against phospholipid-binding proteins, particularly β2GPI, and activate endothelial cells (ECs) in a β2GPI-dependent manner after binding of β2GPI to EC annexin A2. Because annexin A2 is not a transmembrane protein, the mechanisms of APLA/anti-β2GPI Ab–mediated EC activation are uncertain, although a role for a TLR4/myeloid differentiation factor 88–dependent pathway leading to activation of NF-κB has been proposed. In the present study, we confirm a critical role for TLR4 in anti-β2GPI Ab–mediated EC activation and demonstrate that signaling through TLR4 is mediated through the assembly of a multiprotein signaling complex on the EC surface that includes annexin A2, TLR4, calreticulin, and nucleolin. An essential role for each of these proteins in cell activation is suggested by the fact that inhibiting the expression of each using specific siRNAs blocked EC activation mediated by APLAs/anti-β2GPI Abs. These results provide new evidence for novel protein-protein interactions on ECs that may contribute to EC activation and the pathogenesis of APLA/anti-β2GPI–associated thrombosis and suggest potential new targets for therapeutic intervention in antiphospholipid syndrome.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2012
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    American Society of Hematology ; 2011
    In:  Blood Vol. 118, No. 21 ( 2011-11-18), p. 3343-3343
    In: Blood, American Society of Hematology, Vol. 118, No. 21 ( 2011-11-18), p. 3343-3343
    Abstract: Abstract 3343 The antiphospholipid syndrome (APS) is characterized by thrombosis and recurrent fetal loss in patients with antiphospholipid antibodies (APLA). The majority of pathogenic APLA are actually directed against β2-glycoprotein I (β2GPI), an abundant plasma phospholipid binding protein. Microparticles are small phospholipid-rich vesicles that may express tissue factor and are thought to play an important role in thrombosis. Increased release of microparticles may be stimulated by cellular activation or apoptosis, and previous work from our laboratory and others has demonstrated increased levels of circulating microparticles in patients with APS, even far removed from thrombotic events. Though several mechanisms have been proposed for mediating release of microparticles from cells, this process is poorly understood and there is little information available concerning the mechanisms of microparticle release from endothelial cells stimulated by APLA/anti-β2GPI antibodies. To address this issue we assessed the role of non-muscle myosin II motor protein in mediating the release of microparticles from endothelial cells activated by anti-β2GPI antibodies. We observed that incubation of endothelial cells with β2GPI and anti-β2GPI antibodies caused significant increases in the release of microparticles compared to cells treated with β2GPI and control antibodies. Proteomic and biochemical studies demonstrated that anti-β2GPI antibodies caused increased phosphorylation of endothelial cell Myosin II light chain (MLC), an essential step in the activation of Myosin II motor protein. Moreover, examination of endothelial cells stimulated by anti-β2GPI antibodies using confocal microscopy revealed a dramatic increase in the formation of actin-myosin II filaments. To assess the effects of these changes on microparticle release, we inhibited MLC phosphorylation in anti-β2GPI-treated endothelial cells using ML-7, a highly specific inhibitor of MLC. ML-7 caused a significant decrease in the release of microparticles from anti-β2GPI-treated cells. In conclusion, our results demonstrate that non-muscle myosin II motor protein activation by anti-β2GPI antibodies is necessary for the increased release of microparticles from activated cells. These microparticles may play important roles in the propagation of thrombosis and other clinical sequelae observed in patients with APS. Disclosures: No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2011
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Blood, American Society of Hematology, Vol. 122, No. 23 ( 2013-11-28), p. 3808-3817
    Abstract: Activation of endothelial cells by anti-β2GPI antibodies causes myosin RLC phosphorylation, leading to actin-myosin association. In response to anti-β2GPI antibodies, release of endothelial microparticles, but not E-selectin expression, requires actomyosin assembly.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2013
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Blood, American Society of Hematology, Vol. 122, No. 21 ( 2013-11-15), p. 1127-1127
    Abstract: Venous thromboembolism (VTE) is highly prevalent in cancer and has serious consequences, but underlying mechanisms are incompletely understood. Proteomics is a powerful technique to measure protein expression patterns. We utilized a proteomics-based approach to identify novel potential mechanisms of cancer-associated VTE. Methods We analyzed the plasma of matched lung or pancreas cancer patients with and without VTE from the Roswell Park Cancer Institute Biorepository. Plasma samples were depleted of albumin and immunoglobulin by applying them simultaneously to Cibacron blue and protein G-Sepharose resins. The remaining plasma proteins were size-fractionated by SDS-PAGE then analyzed by liquid chromatography-mass spectrometry (LC-MS) for each mass range, following in-gel trypsin digestion. Mascot searches were conducted for protein matches with the NCBI database of the human proteome. Search results were uploaded into Scaffold. Data were filtered based on several criteria including two matching peptides, peptide threshold of 95%, protein threshold of 95% and identified in at least 3 samples. The nSC values were calculated by the Scaffold program and statistical significance was determined by a t-test. Results The cohort comprised 60 patients with lung (N=30; 15 with VTE) or pancreas (N=30; 15 with VTE) cancer. In pancreas cancer patients, 288 proteins were identified of which 66% were present in both VTE and non-VTE samples. Five proteins were more abundant in the thrombotic samples and all were immunoglobulin-derived. These include IgM Fc (nSC = 4.2 and p= 0.02),immunoglobulin kappa chain variable region (MW 13 kDa) (nSC = 6.0 and p= 0.04), Ig kappa chainVKIII-JK3 (nSC = 9.0 and p= 0.03), immunoglobulin heavy chain variable region, (nSC = 13.3 and p= 0.03), and immunoglobulin kappa light chain variable region(only present in VTE samples, p= 0.002). Two proteins were more abundant in the non-VTE samples including an immunoglobulin kappa light chain variable region of different sequence (MW 8 kDa) (nSC=0, p=0.005) and phospholipase D (nSC=0.1, P=0.006). In lung cancer patients, 392 proteins were identified of which 91% were present in both groups. One protein, IgV kappa light chain, was more abundant in VTE samples (only present in VTE samples, p=0.03) and one protein, tetranectin, was more abundant in non-VTE samples (nSC=0.5, p=0.04). There was no overlap between differentially expressed proteins in pancreas and lung cancer specimens. Conclusions We were able to successfully analyze the plasma proteome of a cohort of matched cancer patients with and without VTE. This analysis suggests that immunoglobulin-derived proteins and tetranectin are differentially expressed in cancer patients with and without VTE. Additionally, mechanisms appear to differ based on primary site of cancer. Further studies to investigate the role of these proteins in the pathophysiology of cancer-associated thrombosis and the mechanisms underlying their differential expression are warranted. Disclosures: No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2013
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...